SHORT REPORTS

Vitamin C Supplements and Diabetic Cutaneous Capillary Fragility

Cutaneous capillary strength was investigated in 12 diabetics, six of whom had symptomatic retinopathy (age range 25-71 years) and 24 controls (age range 21-61 years). The effect on the diabetics of a dietary supplement of vitamin C was studied.

Methods and Results

Cutaneous capillary fragility was measured using apparatus described by Hart and Cohen. We modified the procedure by applying a much lower negative pressure to the anterior forearm surface (100 mm Hg instead of 375 mm Hg) and increasing this by 50 mm Hg every minute to a maximum of 300 mm Hg while recording the petechiae observed. The retinæ were examined after the blood was drawn for vitamin C and other assays (to be reported elsewhere). Dietary vitamin C intake was assessed over one week and in half the diabetics and a quarter of the non-diabetics the intake was less than the recommended 315 mg/week.

The 12 diabetics were divided randomly into two groups. Group 1 was given placebo for one month followed by vitamin C (1 g/day) for two months. Group 2 was given vitamin C supplements for two months and then placebo for one month. Each month cutaneous capillary fragility was assessed, blood vitamin C estimated, and the fundi examined.

In all subjects an increase of negative pressure led to a logarithmic increase in the number of petechiae observed. The diabetics showed petechiae at much lower negative pressures than the controls and all diabetics with retinopathy had very fragile capillaries. In group 1 cutaneous capillary fragility did not change after placebo treatment, but the capillary strength in all diabetics (in both groups) improved during vitamin C treatment. In group 2 the capillary strength of four of the six diabetics deteriorated at the end of the final month on placebo treatment. No retinal changes were observed during vitamin C treatment.

Discussion

Our technique provided a simple measurement of capillary fragility. The results at the initial assessment confirmed the findings of Hunter et al. that diabetics, particularly those with complications, have more fragile skin capillaries than normal (see fig.). Though many diabetics had low vitamin C intakes, capillary fragility was not related to vitamin C intake in the group as a whole. Furthermore, since diabetics with an intake above the recommended 45 mg/day had fragile capillaries and daily 1 g supplements brought their capillary strength towards normal, diabetics probably need more vitamin C than normal people (the effects of vitamin C supplements were not maintained after withdrawal of treatment).

Studies of the effect of insulin on the exchange of vitamin C in the peripheral tissues indicated that the response (and thus possibly the tissue distribution of the vitamin) differed in diabetics and normal people, though glucose uptake and plasma vitamin C levels were similar.

Can high vitamin C intakes of up to 7000 mg/week prevent retinopathy as well as protecting skin capillary strength? The retina normally has a very high concentration of ascorbic acid but we do not know whether raising the circulating levels of vitamin C can overcome any impaired ability to concentrate the vitamin in the retina. Nevertheless, there were no retinal changes during vitamin treatment, but in one of the diabetics a fresh crop of small red dots, taken to be retinal haemorrhages, occurred after withdrawal. Possibly a sudden reduction of vitamin C intake, which may lead to a dramatic fall in plasma and tissue levels, may also cause adverse local effects in diabetics.

4 Cox, B. D., et al., Clinical Science and Molecular Medicine, 1974, 47, 63.

Anaphylactic Reactions after Use of CT 1341 (Althesin)

CT 1341 (Althesin) is a mixture of two steroids, alfaxalone and alphadolone acetate, dissolved in 0.25% saline with 20% polyoxyethylated castor oil (Cremophor EL). These steroids are weakly antoestrogenic with no other steroid properties. CT 1341 is a rapid and short-acting anaesthetic induction agent, producing less cardiovascular and respiratory depression than barbiturates and no "hang-over."

At Good Hope General Hospital CT 1341 was used for two years in 3500 anaesthetics; four patients with no history of allergy suffered severe hypersensitivity reactions.

Case Reports

Case 1.—A healthy 17-year-old boy had a fractured tibia reduced under general anaesthesia using intravenous CT 1341 5 ml, suxamethonium 75 mg, and endotracheal intubation and maintained with nitrous oxide, oxygen, and halothane. No problems occurred. Eleven days later the same anaesthetic technique was used for manipulation. He developed bronchospasm, tachycardia (>180 beats/min), and hypotension (systolic blood pressure <90 mm Hg). Hydrocortisone 500 mg, aminophylline 250 mg, and Horm's solution 500 ml were given intravenously. The bronchospasm responded rapidly, but hypotension persisted for five hours. Skin tests3 to both CT 1341 and suxamethonium gave negative results.

Case 2.—A healthy 44-year-old woman was admitted for skin grafting. Anaesthesia was induced intravenously with althesin 7 ml, suxamethonium 50 mg, and endotracheal intubation and maintained with nitrous oxide, oxygen, and halothane. Diazepam 10 mg was also given. A month later the same anaesthetic technique was used again but with CT 1341 6 ml and diazepam 5 mg. After intubation she developed tachycardia (>100 beats/min), bronchospasm, cyanosis, generalized urticaria, and severe hypotension. Her condition improved after ventilation with oxygen and intravenous hydrocortisone 400 mg and dextran 70 500 ml. Hypotension lasted for one hour. Skin tests2 produced positive results to CT 1341 and propanidid but not to suxamethonium and diazepam.

Case 3.—A healthy 19-year-old man had a fractured ankle reduced under general anaesthesia using CT 1341 5 ml intravenously with no ill effects. Thirteen days later the same technique was used for manipulation, but he started to cough and developed a deep flush all over his body before all the CT 1341 had been given. He was intubated, using suxamethonium 100 mg, but became pale and pulseless. After intubation with oxygen he had a tachycardia (>180 beats/min), remained hypotensive (systolic blood pressure <70 mm Hg), and had a rash. Hydrocortisone 500 mg and chlorpheniramine 10 mg were given intravenously and Dextran 70 (in saline) 500 ml infused rapidly intravenously. He recovered but was hypotensive for one and a half
hours. No bronchospasm occurred. Skin tests showed a definite reaction to CT 1341 and propanidid (1/10 with saline) but not to saline alone.

**Case 4.** A healthy 15-year-old girl had a fractured tibia manipulated under general anaesthesia using propanidid 500 mg intravenously and maintained on nitrous oxide, oxygen, and halothane. Thirteen days later the procedure was repeated, but CT 1341 5 ml was used for induction, after which the patient showed coughing and ventilation was inadequate. Despite intubation using suxamethonium 100 mg inflation was difficult owing to bronchospasm. Facial oedema, tachycardia, and hypotension (systolic blood pressure 50 mm Hg) developed. Hydrocortisone 200 mg plus another 500 mg and aminophylline 250 mg were given intravenously and a rapid intravenous infusion was begun. The bronchospasm subsided rapidly and blood pressure became normal over the next hour, during which a percutal rash developed over the neck and shoulders. This and the facial oedema disappeared after three days. No skin tests were performed.

**Discussion**

In August 1974 the Committee on Safety of Medicines had received 62 reports on CT 1341 Althesin, 21 about allergic reactions. Dundee reported 13 such reactions with thiopentone, and 23 with propanidid. The incidence of CT 1341 sensitivity was estimated as less than 1 in 25 000. Tammisto et al. suggested that hypersensitivity might be due to Cremophor EL; such a response had been shown in dogs. Hypotensive reactions to Cremophor EL have been reported in humans but not with clinical doses. Histamine release has been shown in response to CT 1341 and propanidid (both contain Cremophor EL) but not to Cremophor EL alone. CT 1341 was withdrawn from routine use at this hospital.

I thank the members of the anaesthetic department at Good Hope General Hospital for permission to report their cases, and for helpful advice; and Miss R. A. Bosworth for secretarial help.

---

**Perforation of Small Bowel Due to Slow Release Potassium Chloride (Slow-K)**

Perforation of the small bowel is a recognized complication of enteric-coated potassium chloride preparations. Slow release preparations of potassium chloride were thought to be free of this risk, but we report here a case of perforation due to Slow-K.

**Case Report**

A 57-year-old man with a long history of hypertension and multiple strokes was admitted from a long-stay hospital as a surgical emergency. He had the symptoms and signs of a perforated abdominal viscus. In the six months before admission he had received two tablets (2 × 8 mmol) of Slow-K daily—sulphobutyrate (Amprenor) 5 mg each morning, and nitrates (Naprosyn) 5 mg each night. He had been fed a low-volume, high-calorie liquid diet for some months before his transfer as he was otherwise difficult to feed. At laparotomy a fibrous stricture was found about half way along the small bowel. This was about 0.5 cm long and had narrowed the lumen to about 0.3 cm. A perforation was present at this point. The lesion was resected and end-to-end anastomosis performed. After recovery his gastrointestinal transit time was estimated twice using oral Carmine dye and was eight days, mouth to anus.

Histological sections showed superficial acute mucosal ulceration, one area showing acute deep ulceration and perforation (see fig.). There was underlying destruction of the muscularis mucosa in the ulcerated area and acute inflammatory infiltration through the muscularis propria. The picture was consistent with a perforated, and almost certainly iatrogenic, ulcer with no evidence of malignancy.

**Discussion**

The thiazide diuretics are potent and safe but need potassium supplementation. Supplements were available as enteric-coated tablets of potassium chloride, either separately or compounded with the diuretic itself. The enteric coating was necessary because potassium chloride irritates the stomach. Experience showed that it also irritated the small bowel when the enteric coating breaks down and releases the potassium chloride. By 1965 over 300 cases of small bowel ulceration and perforation had been reported. The important factor in damage to the small bowel is the high local concentration of potassium chloride, which causes oedema, haemorrhage, erosion, and cicatrizening stenosis in turn; the lesion is essentially a haemorrhagic infarct with venous thrombosis.

Other potassium compounds—for example, bicarbonate—while safer, are metabolically unacceptable, the chloride ion being essential. Slow-release tablets consisting of potassium chloride embedded in a wax matrix from which it slowly dissolves became available, the rationale being that these would give a slow and sustained release over a length of small bowel, thereby preventing a high local concentration of potassium chloride. Slow-K in particular was widely recommended as the drug of choice, as it was supposed to be free of the risk of haemorrhage or ulceration. In all published cases of ulceration due to Slow-K, there has been local stasis in the oesophagus due to cardiomegaly.

Our patient, whose drug treatment was accurately known (the other drugs he was receiving were blameless), had delayed intestinal transit, which abolished the "protective" effect of slow-release potassium. The stricture he developed led to further stasis and then perforation.

Patients likely to have delayed intestinal transit—the elderly, immobile, or those taking a low-volume diet—should be given any necessary potassium supplementation in a well-diluted liquid form with or after food.

We thank Mr. M. Golby for allowing us to describe a patient under his care, and Drs. R. A. Caldwell, and E. Sevedee for the histological analysis.

---


---

Royal Devon and Exeter Hospital (Wonford), Exeter EX2 5D}

M. A. FARQUHARSON-ROBERTS, M.B., B.S., Senior House Officer, General Surgery

A. E. B. GIDDINGS, M.B., F.R.C.S., Senior Surgical Registrar

A. J. NUNN, B.PHARM., M.P.S., Staff Pharmacist